Cryo-Cell International, Inc. - 10-Q Summary
Business Context and Reporting Period
Company: Cryo-Cell International, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: August 31, 2010
Business Overview: The Company is engaged in cellular processing and cryogenic storage, primarily focusing on umbilical cord blood stem cells (U-Cord) and menstrual stem cells (C'ellé). Revenue is derived from processing/storage fees and licensing agreements with international affiliates.
Key Financial Metrics (Nine Months Ended Aug 31, 2010)
| Metric | Value |
|---|---|
| Total Revenue | $13,079,047 |
| Net Income | $3,016,603 |
| Net Income Per Share (Basic) | $0.26 |
| Operating Cash Flow | $1,703,285 |
| Cash and Cash Equivalents | $7,880,649 |
| Total Assets | $17,732,570 |
| Total Liabilities | $19,736,366 |
| Stockholders' Deficit | $(2,003,796) |
Margins: Cost of sales was 25% of revenue. Operating income was $2,490,584.
Material Changes vs. Prior Period
- Revenue: Decreased 3% to $13.08 million compared to $13.53 million in the prior year period. This was driven by a 3% decrease in processing/storage fees and a 9% decrease in licensee income due to timing of agreements.
- Net Income: Increased significantly to $3.02 million from $1.76 million in the prior year. This increase was primarily due to a non-cash income tax benefit of approximately $1.68 million resulting from the reversal of a portion of the deferred tax valuation allowance.
- Cost of Sales: Decreased 6% to $3.32 million, attributed to operational efficiencies and the cancellation of a contract with Safti-Cell, which reduced costs by approximately $208,000.
- Operating Expenses: Marketing, general, and administrative expenses increased 5% to $6.97 million due to increased sales initiatives.
Guidance, Outlook, and Risks
Management Commentary: Management reversed a $1.79 million portion of its deferred tax valuation allowance based on profitability in seven of the last eight quarters and positive expectations for future taxable income. The Company has retained an investment banking firm to explore strategic acquisitions.
Liquidity: The Company anticipates that cash on hand and operating cash flows will be sufficient to fund operations for at least the next 12 months. No long-term indebtedness exists as of October 1, 2010.
Risks and Contingencies:
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective due to a material weakness regarding the accrual of licensee royalties. Remediation steps have been taken, but controls have not operated long enough to be deemed effective.
- Licensee Dependence: Revenue relies on international licensees; deterioration in their financial condition could impact earnings.
- Regulatory and Competition: Risks include increased government regulation of stem cell storage and competition from public cord blood banks.
- Acquisition Risks: Potential strategic acquisitions may not be identified, financed, or integrated successfully.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the assumptions regarding future taxable income that justified the $1.79 million reversal of the deferred tax valuation allowance.
- Internal Control Remediation: Monitor the effectiveness of new controls regarding licensee royalty accruals, as the current controls are deemed ineffective.
- Licensee Performance: Review the financial health and royalty payment status of key international licensees (e.g., Mexico, India, Venezuela) given the 9% drop in licensee income.
- Acquisition Strategy: Assess the potential dilution or debt impact of any strategic acquisitions the Company is currently exploring.
- Deferred Revenue: Note the significant deferred revenue balance ($13.04 million total) and the timing of its recognition over long-term storage contracts.